Priyanka Yalamanchili

Priyanka Yalamanchili

Auto-generated profile, based on publicly available information

Priyanka Yalamanchili

Rutgers University New Brunswick New Jersey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022 in Pharmaceutical Medicine
Verified
Journal Article
Closed access
PDF file
MSMaribel Salas
Maribel Salas
JPJan Petracek
Jan Petracek
PYPriyanka Yalamanchili
Priyanka Yalamanchili
OAOmar Aimer
Omar Aimer
DKDinesh Kasthuril
Dinesh Kasthuril
TBTina Bostic
Tina Bostic

10 December 2024 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PYPriyanka Yalamanchili
Priyanka Yalamanchili
LLLydia Y. Lee
Lydia Y. Lee
GBGreta Bushnell
Greta Bushnell
MMMelissa Mannion
Melissa Mannion
CDChintan V. Dave
Chintan V. Dave
DHDaniel B Horton
Daniel B Horton
Objective: The objective of this study is to describe recent trends in disease‐modifying antirheumatic drug (DMARD) use for children with juvenile idiopathic arthritis (JIA) in the United States.Methods: We used commercial claims data (2000–2022) to perform a serial cross‐sectional utilization study of children aged 1 to 18 that were diagnosed with JIA. Initiations of conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs) were identified after a ≥12‐month baseline and expressed as a percentage of all new DMARD initiations per year, by category, class, and individual agent. Trends were evaluated using linear regression. We also examined the first bDMARDs and tsDMARDs initiated after csDMARD monotherapy.Results: We identified 20,258 new DMARD use episodes among 13,696 individuals (median age 14 years, 67.5% female). csDMARDs, although most used overall, declined from 89.5% of new use episodes to 43.2% (2001–2022, P < 0.001 for trend). In contrast, bDMARD use increased (10.5–50.0%, P < 0.001). For tumor necrosis factor inhibitors (TNFi), etanercept peaked at 28.3% in 2006 and declined to 4.2% in 2022 (P = 0.002). Meanwhile, adalimumab use doubled (7.0–14.0%, 2007–2008) after JIA approval, increasing further following a less painful formulation release (20.5% in 2022, P < 0.001). However, overall TNFi use has declined with increasing use of other bDMARDs and tsDMARDs, particularly ustekinumab, secukinumab, and tofacitinib. By 2022, adalimumab was the most common b/tsDMARD initiated first after csDMARDs (77.8%).Conclusion: Among commercially insured children with JIA in the United States, new b/tsDMARD use is rising and new csDMARD use is declining. For b/tsDMARDs, adalimumab is most used and is the predominant b/tsDMARD initiated first after csDMARDs. Patterns in DMARD use for JIA have evolved relative to multiple factors, including regulatory approvals and tolerability.

15 March 2024 in Biomarkers in Medicine
Verified
Journal Article
Closed access
EWEric Wang
Eric Wang
MHMackenzie Henderson
Mackenzie Henderson
PYPriyanka Yalamanchili
Priyanka Yalamanchili
JCJenilee Cueto
Jenilee Cueto
ZIZahidul Islam
Zahidul Islam
MSMaribel Salas
Maribel Salas
Breast cancer treatments have evolved rapidly, and clinically meaningful biomarkers have been used to guide therapy. These biomarkers hold utility within the drug development process to increase th...

1 January 2023 in Biomarker Insights
Verified
Journal Article
Open access
MSMaribel Salas
Maribel Salas
Maxine Gossell-WilliamsMaxine Gossell-Williams
Maxine Gossell-Williams
PYPriyanka Yalamanchili
Priyanka Yalamanchili
SDSameer Dhingra
Sameer Dhingra
MMMarina A Malikova
Marina A Malikova
TJToluwalope Junaid
Toluwalope Junaid
Background: The use of biomarkers varies from disease etiognosis and diagnosis to signal detection, risk prediction, and management. Biomarker use has expanded in recent years, however, there are limited reviews on the use of biomarkers in pharmacovigilance and specifically in the monitoring and management of adverse drug reactions (ADRs). Objective: The objective of this manuscript is to identify the multiple uses of biomarkers in pharmacovigilance irrespective of the therapeutic area. Design: This is a systematic review of the literature. Data Sources and Methods: Embase and MEDLINE database searches were conducted for literature published between 2010-March 19, 2021. Scientific articles that described the potential use of biomarkers in pharmacovigilance in sufficient detail were reviewed. Papers that did not fulfill the United States Food and Drug Administration (US FDA) definition of a biomarker were excluded, which is based on the International Conference on Harmonisation (ICH)−E16 guidance. Results: Twenty-seven articles were identified for evaluation. Most articles involved predictive biomarkers (41%), followed by safety biomarkers (38%), pharmacodynamic/response biomarkers (14%), and diagnostic biomarkers (7%). Some articles described biomarkers that applied to multiple categories. Conclusion: Various categories of biomarkers including safety, predictive, pharmacodynamic/response, and diagnostic biomarkers are being investigated for potential use in pharmacovigilance. The most frequent potential uses of biomarkers in pharmacovigilance in the literature were the prediction of the severity of an ADR, mortality, response, safety, and toxicity. The safety biomarkers identified were used to evaluate patient safety during dose escalation, identify patients who may benefit from further biomarker testing during treatment, and monitor ADRs.